Search

Opaganib

Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.

EDP1815

investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as

Regorafenib

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...

Ethinylestradiol

Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitu...

Recombinant Bacterial ACE2 Receptors-like Enzyme

B38-CAP is structured as a carboxypeptidase and derived from _Paenibacillus sp._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2

Stanozolol

Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.

PPI-2458

such as cancer and rheumatoid arthritis. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

Rindopepimut

The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.

LErafAON

Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

Chlorphenesin